Yutaka Shimazu

26PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCellular immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 08, 2026
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.

|Jun 28, 2025
Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma.

Yutaka Shimazu, Kenta Murotani, Hiroki Kitabayashi

|Nov 05, 2024
Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.

Yosuke Okada, Noriaki Tachi, Yutaka Shimazu

|Aug 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.

Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa

|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.

Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda

|May 17, 2024
The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.

Yutaka Shimazu, Junya Kanda, Kazuhito Suzuki

Pageof 5

Frequent Collaborators

5 joint publications

Junya Kanda

3 joint publications

Noriko Doki

3 joint publications

Yoshiyuki Onda

3 joint publications

Naoyuki Uchida